Agile Therapeutics was founded in 1997 on the principle that women want and need more convenient contraceptive options. Agile has a pipeline of investigational contraceptive products in late-stage clinical development that represent significant near-term revenue potential. These contraceptives are transdermal patches based on a proprietary delivery technology developed by Agile. The company will compete in the more than $4 billion contraceptive market.

The patches use the proprietary transdermal delivery technology developed by Agile, Skinfusion^®, and are designed to be soft and flexible with a silky feel. The Agile patch has demonstrated favorable wearability and adhesion in clinical trials.

Agile Therapeutics is headquartered in Princeton, NJ.